Oxcia AB Announces Antiviral Potential of OGG1 Inhibitors, Including activity Against Zika Virus
Stockholm, Sweden – Oxcia AB (publ) today highlighted the antiviral activity demonstrated by its OGG1 inhibitor series, including compounds OXC-201 (TH5487) and TH6744, against a range of viruses including Zika virus, SARS-CoV-2, Ebola, and CCHF virus. The compounds’ antiviral effect is believed to function by destabilizing the host cell’s chaperon protein HSP70, thereby inhibiting viral protein synthesis and replication.
zika virus gained global attention in 2015 with an outbreak in Brazil linked to a surge in cases of congenital Zika syndrome (CZS), a condition characterized by changes in the progress of the central nervous system. Between 2015 and 2022, Brazil’s Ministry of Health reported over 20,000 suspected cases of CZS, and the syndrome remains a global health concern.
OXC-201 is currently in development as a potential treatment for idiopathic pulmonary fibrosis (IPF), with potential applications in other fibrotic conditions, inflammatory diseases, and viral infections. TH6744 is an analogue of OXC-201. Both are part of a series of OGG1 inhibitors.
Oxcia’s technology platform, O2-DDR, focuses on oxidative DNA injuries and DNA Damage Response, aiming to develop new treatments for diseases caused by cancer or inflammation. The company’s portfolio includes OXC-101, in early clinical development as a cancer therapy, and OXC-201, in preclinical development for IPF, alongside exploratory projects such as psoriasis research.
Further facts is available from Ulrika Warpman Berglund, CEO of oxcia AB, at +46 (0) 73 270 9605 or ulrika.warpmanberglund@oxcia.com. Details can also be found at www.oxcia.com.
